IngredientsAlpha-lactalbumin (α-LA) is a small (Mr 14,200), acidic (pI 4–5) globular protein found in the whey fraction of milk in all mammals. Its molecular weight is 14,178 Da, and its isoelectric point lies between 4.2 and 4.5. In scientific nomenclature it is designated α-lactalbumin, abbreviated α-LA or α-Lac; the gene encoding the human form is LALBA. The protein is also formally registered as the allergen Bos d 4 in the context of cow's milk allergy.
α-Lactalbumin is a Ca2+-binding milk protein very important from several points of view. Most α-lactalbumins, including human, guinea pig, bovine, goat, camel, equine and rabbit proteins, consist of 123 amino acid residues. It is a small, monomeric (14.19 kDa) Ca2+-binding protein stabilized by four disulfide bridges.
The sequence of α-lactalbumin shows a strong similarity to that of lysozymes, specifically the Ca2+-binding c-lysozyme. These two proteins share much of their physical structure but contain less than half of the same amino acid sequence and therefore vary in function drastically. The expected evolutionary history is that gene duplication of c-lysozyme was followed by mutation, resulting in the loss of lysozyme catalytic activity in α-lactalbumin.
The mean concentration of α-LA in mature human milk is 2.44 ± 0.64 g/L during lactation. α-LA accounts for about 25–35% of the total milk protein content and approximately 41% of the whey protein content. In contrast, alpha-lactalbumin is still low in standard infant formulas due to its lower concentration in bovine milk, where it constitutes approximately 3.5% of total protein, or 17% of the whey protein.
Whey — a component of milk and a useful by-product of the dairy industry's casein and cheese-making — contains a range of proteins, including lactalbumin (LA), lactoglobulin (LG), bovine serum albumin (BSA), heavy chain and light chain immunoglobulins (IGs), lactoferrin (LF), glycomacropeptide (GMP), and lactoperoxidase. Whey proteins consist primarily of α-lactalbumin and β-lactoglobulin.
Alpha-lactalbumin has two prominent forms: the holo-state and the apo-state. The holo-state is the natural form — folded and bound by calcium. The apo-state occurs in acidic conditions and is associated with the release of calcium ions and beta-sheet unfolding. In the absence of bound metal ions, α-LA is in the molten globule-like state. The binding of metal ions, and especially of Ca2+, increases stability of α-LA against the action of heat, various denaturing agents, and proteases.
Alpha-lactalbumin, a globular protein found in all mammalian milk, has been used as an ingredient in infant formulas. The protein can be isolated from milk using chromatography/gel filtration, membrane separation, enzyme hydrolysis, and precipitation/aggregation technologies. Commercial preparations include whey protein concentrates enriched to varying degrees of purity. The concentration of α-lactalbumin protein in powdered dairy compositions is at least 70 wt.% on a protein basis in high-purity fractions. In supplement contexts, α-LA is available as a standalone powder and as a fraction within whey protein concentrates or isolates.
The modern isolation and study of α-lactalbumin as a distinct entity is a 20th-century development, but its vehicle — whey — has a documented history spanning millennia. Archaeologists have found the earliest known examples of cheesemaking from over 7,000 years ago in Poland, confirming that at that time there was knowledge of curds and whey. Ancient civilizations recognized whey's value long before modern nutritional science. Hippocrates, the Greek physician often called the father of medicine, reportedly prescribed whey to his patients around 400 BC as a tonic for health and vitality. For thousands of years across Europe, whey was consumed as a health beverage, fed to livestock, and used in early folk medicine.
In 18th-century Switzerland, "whey cures" at Alpine spas were fashionable among the wealthy. Visitors would travel to mountain towns to drink fresh whey daily, believing it aided digestion, skin health, and general well-being. There was no understanding of protein science behind these practices — just empirical observation that whey seemed to make people feel better.
Throughout history, whey was a popular drink in inns and coffee houses. In culinary traditions, whey was used to produce whey cheeses such as ricotta, Norwegian brunost, and whey butter.
In the 1930s, scientists were able to isolate two of the proteins in whey, β-lactoglobulin and α-lactalbumin. This propelled more discoveries of the immune-boosting compounds in whey protein along with its overall nutrient composition, spurring interest in finding ways to concentrate and dry whey for longer preservation. The specific biological role of α-lactalbumin in lactose biosynthesis was elucidated in subsequent decades, with detailed structural and functional characterization continuing into the 1990s and 2000s.
α-LA is one of the two components of lactose synthase, which catalyzes the final step in lactose biosynthesis in the lactating mammary gland. α-Lactalbumin forms the regulatory subunit of the lactose synthase (LS) heterodimer and β-1,4-galactosyltransferase (beta4Gal-T1) forms the catalytic component. Together, these proteins enable LS to produce lactose by transferring galactose moieties to glucose.
Alpha-lactalbumin is among the most prevalent nutritious protein compounds in both cow's and human milk. It comprises between 20 and 25% of whey proteins and offers a broad range of highly advantageous amino acids, consisting of a convenient source of branched-chain and essential amino acids.
Since α-lactalbumin in human and bovine milk exhibits a similar and favorable amino acid composition with abundant essential amino acids, especially tryptophan and cysteine, increasing its concentration in infant formula could enable further reduction of protein concentration with a composition and amino acid profile more similar to that of breast milk.
Two amino acids are particularly notable in the context of its supplemental use:
α-Lactalbumin is a simple model Ca2+ binding protein. It has a strong Ca2+ binding site, which also binds Mg2+, Mn2+, Na+, and K+, and several distinct Zn2+ binding sites. The binding of cations to the Ca2+ site increases protein stability against the action of heat and various denaturing agents. α-Lactalbumin is a calcium-binding protein that can also bind iron and zinc with lower affinity. Current evidence suggests that α-lactalbumin has a stimulating effect on the absorption of these minerals.
The activity of α-Lac may be associated with tryptophan and serotonin production, cysteine as a direct precursor for production of the antioxidant glutathione, or with peptides such as pentapeptides linked by a disulfide bridge or glycyl-leucyl-phenylalanine produced by trypsin digestion in the small intestine. These peptides have been shown to have antibacterial activity in animal and isolated cell systems; however, the physiological significance of these peptides in the human gastrointestinal tract remains largely unknown.
α-LA is appreciated as a source of peptides with antitumor and apoptosis, antiulcerative, immune-modulating, antimicrobial, antiviral, antihypertensive, opioid, mineral-binding, and antioxidative bioactivities, which may be utilized in the production of functional foods. A specific example: alpha-lactorphin (Tyr-Gly-Leu-Phe) from alpha-lactalbumin has opioid activity and has been shown to lower blood pressure in animal models. Bioactive peptides in α-LA are released during the fermentation or ripening of dairy products by starter and nonstarter microorganisms and during digestion by gastric enzymes.
The central mechanism underlying α-LA's neurological and sleep-related effects involves competitive transport across the blood-brain barrier. Large neutral amino acids (LNAAs) — including phenylalanine, tyrosine, leucine, isoleucine, and valine — compete with tryptophan for the same transporter into the brain. Because α-LA has a high tryptophan-to-LNAA ratio relative to other proteins, its consumption increases the plasma Trp:LNAA ratio and thereby favors tryptophan entry into the brain. Alpha-lactalbumin, a type of whey-derived protein, possesses a similar postprandial and digestive characteristic but has higher tryptophan than whey protein. As tryptophan is the precursor to serotonin, this change suggested an increasing synthesis of serotonin in the central nervous system (CNS).
HAMLET (human alpha-lactalbumin made lethal to tumor cells) is a tumoricidal complex consisting of partially unfolded protein and fatty acid and was first identified in casein fractions of human breast milk. The complex consists of partially unfolded alpha-lactalbumin and oleic acid, and both the protein and the fatty acid are required for cell death. Because native alpha-lactalbumin itself cannot trigger cell death, HAMLET's remarkable tumor-selective cytotoxicity has been strongly correlated with the conformational change of the protein upon forming the complex. HAMLET kills cancer cells but not healthy, differentiated cells. Although cancer cells have inactivated their apoptotic pathways, HAMLET is capable of destroying them, both those of human origin and those from various other species. HAMLET has shown antitumor activity in more than 40 different lymphoma and carcinoma cell lines. This remains primarily a research area and HAMLET is not an established clinical therapy.
This is the area with the strongest and most direct clinical evidence base for α-lactalbumin.
Clinical studies have shown that lowering the protein content of infant formula while increasing the proportion of α-lactalbumin can result in plasma concentrations of essential amino acids similar to those in breastfed infants. Since excessive protein in infant formulas is associated with potential risks, enriching formula with α-lactalbumin may offer benefits while permitting reduced total protein.
A key randomized controlled trial: healthy term formula-fed infants 5–14 days old were randomized in a controlled, double-blind trial to standard formula (SF: 14.1 g/L protein) group (n=112) or experimental formula (EF: 12.8 g/L protein) group (n=112) for 120 days; a human milk reference group (n=112) was included. The trial demonstrated that the new lower-protein α-lactalbumin-enriched formula is appropriate for term infants as evidenced by age-appropriate growth, markers of protein status, plasma essential amino acid concentrations, and gastrointestinal tolerance. Infants randomized to the lower protein formula had growth outcomes similar to human milk-fed infants in terms of weight gain.
A subsequent randomized, prospective, double-blinded intervention trial evaluated: term infants receiving standard formula (SF: 2.2 g protein/100 kcal; n=83) or low-protein formulas with α-lac-enriched whey (α-lac-EW: 1.75 g protein/100 kcal; n=82) or CGMP-reduced whey (CGMP-RW: 1.76 g protein/100 kcal; n=80) from 2 to 6 months, with breastfed infants (n=83) as reference. Blood urea nitrogen did not differ between low-protein formula groups and breastfed infants, but was lower than in standard formula. Essential amino acids were similar or higher in α-lac-EW and CGMP-RW compared to breastfed infants. The conclusion was that low-protein formulas enriched with α-lac-enriched whey support adequate growth, with more similar weight gain to breastfed infants and metabolic profiles closer to breastfed infants.
Clinical trials have confirmed that formulas enriched with α-lactalbumin are safe, support adequate growth, increase energetic efficiency, and improve gastrointestinal tolerance in infants. Protein intake is higher in formula-fed than in breast-fed infants during infancy, which may lead to an increased risk of being overweight. Applying alpha-lactalbumin-enriched whey to infant formula may enable further reduction of formula protein by improving the amino acid profile.
Evidence strength: Strong for infant growth support, amino acid adequacy, and protein reduction feasibility, from multiple RCTs and a substantial body of clinical literature.
The foundational human clinical trial in this area was a prospective, randomized, double-blind crossover study. Markus et al. (2000) reported on a study of the ability of alpha-lactalbumin to help high- and low-stress-vulnerable adults cope with stress. Enrollees were 29 highly stress-vulnerable subjects and 29 relatively stress-invulnerable subjects, aged 17–34 years. The plasma Trp-LNAA ratio was 48% higher after the alpha-lactalbumin diet than after the casein diet (P=0.0001). In stress-vulnerable subjects this was accompanied by higher prolactin concentrations (P=0.001), a decrease in cortisol (P=0.036), and reduced depressive feelings (P=0.007) under stress. The authors concluded that consumption of a dietary protein enriched in tryptophan increased the plasma Trp-LNAA ratio and, in stress-vulnerable subjects, improved coping ability, probably through alterations in brain serotonin.
A follow-up crossover trial (Markus et al., 2002, Am J Clin Nutr, PMID 12036812) found that whey protein rich in alpha-lactalbumin increases the ratio of plasma tryptophan to the sum of the other large neutral amino acids and improves cognitive performance in stress-vulnerable subjects.
An enhancement of mood states with a lower feeling of depression, and a decreasing of cortisol has been reported after experimental stress following ingestion of alpha-lactalbumin.
Evidence strength: Modest. Results are consistent across a small number of human crossover trials, but sample sizes are small (n≈29–58 per study), effects appear most pronounced in stress-vulnerable individuals, and all trials come from one primary research group. Independent replication in larger populations is limited.
Insufficient sleep is a growing global problem. Previous reviews investigating the effect of diet on sleep have highlighted the amino acid tryptophan as a promising sleep-promoting nutrient, with the richest food source of tryptophan, α-lactalbumin, requiring further investigation. A 2024 systematic review aimed to review the existing evidence of the association between α-lactalbumin and sleep.
Sleep-onset latency was the primary sleep metric improved following evening supplementation of α-lactalbumin (≤3.5 hours pre-sleep), with no studies observing any negative associations with sleep. Data from this review suggest that individuals who have difficulty initiating sleep may benefit most from pre-sleep α-lactalbumin supplementation.
A parallel search retained six original studies that quantified sleep outcomes in athletes receiving α-lactalbumin. Putative mechanisms identified include: (i) modulation of the tryptophan–serotonin–melatonin axis, (ii) anti-inflammatory action, and (iii) attenuation of oxidative stress.
Evidence strength: Preliminary to moderate. The 2024 systematic review (Barnard, Journal of Sleep Research) represents the most rigorous synthesis to date, identifying sleep-onset latency as the most consistently improved parameter. The number of qualifying studies and sample sizes remain small. Direct human evidence for broader improvements in sleep architecture or duration requires further research.
Enrichment of α-lactalbumin in infant formula led to higher circulating tryptophan and increased serotonin levels in the striatum of neonatal piglets, and also increased metabolic products from the kynurenine and indole pathways, which were predominantly excreted in urine. Despite these increases, the activity of the kynurenine pathway in the liver was lower, possibly mediated by reduced circulating cortisol, thus increasing brain tryptophan availability and favoring serotonin synthesis.
Clinical trials have confirmed that formulas enriched with α-lactalbumin are safe, support adequate growth, increase energetic efficiency, and improve gastrointestinal tolerance in infants. Additionally, adequate dietary tryptophan is essential for infant cognitive and brain development, as it serves as a precursor for serotonin biosynthesis within the brain.
Evidence strength: The neurodevelopmental tryptophan-serotonin pathway data is primarily animal (neonatal piglet model) as of the most recent studies. The clinical infant formula trials establish safety and growth adequacy but do not directly measure brain serotonin or long-term neurocognitive outcomes in human infants.
Whey protein, the most commonly used dietary protein in post-exercise recovery, has been shown to be superior to other dietary proteins in enhancing muscle protein re-synthesis. Alpha-lactalbumin, a type of whey-derived protein, possesses a similar postprandial and digestive characteristic but has higher tryptophan than whey protein. To date, few studies have reported the application of alpha-lactalbumin in the exercise situation.
Alpha-lactalbumin has received relatively little attention for use in adult nutrition compared to infant nutrition, making direct head-to-head RCT data on muscle outcomes thin. The mechanistic rationale (leucine content, essential amino acid completeness) is reasonable, but the direct human exercise trial evidence for α-LA specifically — as opposed to whey protein broadly — remains limited.
Evidence strength: Weak to preliminary for exercise-specific outcomes. The mechanistic basis is scientifically plausible, but dedicated human RCTs comparing isolated α-LA to other protein sources for muscle outcomes are few in number.
α-LA possesses bactericidal and antiviral activities. α-Lactalbumin has been shown to inhibit the growth of several potential pathogens both in vitro and in vivo. Interestingly, several of the functions associated with α-lactalbumin may actually be attributable to peptides released during its digestion. Although these peptides are likely formed in the upper gastrointestinal tract, they may exert their functions as they pass through the distal part of the small intestine and the colon.
α-Lactalbumin promotes healthy bacterial strains such as Lactobacillus acidophilus, Bifidobacterium short, and Bifidobacterium longum. These bacteria produce short chain fatty acids (SCFA) which improve the gut biome. Furthermore, α-lactalbumin stimulates the growth of beneficial microorganisms like bifidobacteria, which reduce pH in the intestinal tract and thereby may enhance mineral absorption.
Evidence strength: Primarily in vitro and animal data for antimicrobial peptide effects. The prebiotic/microbiota-modulating effects are consistent but largely observational or based on indirect infant clinical trial outcomes; direct mechanistic human trials are sparse.
HAMLET has broad antitumor activity in vitro, and its therapeutic effect has been confirmed in vivo in a human glioblastoma rat xenograft model, in patients with skin papillomas, and in patients with bladder cancer. The mechanisms of tumor cell death remain unclear, however. Over the past several years, additional work has further characterized the structure and function of HAMLET and its clinical applications are currently under investigation. However, in order to develop effective therapies, more must be known about the mechanism of action of HAMLET.
Evidence strength: Very preliminary. HAMLET is not a recognized or approved therapeutic agent. Evidence is primarily preclinical (cell lines and animal models), with only very limited early-phase human studies. Dietary supplementation with α-LA does not equate to HAMLET therapy, as HAMLET requires specific partially unfolded protein conformations and oleic acid co-complexing.
The alpha-lactalbumin protein binds divalent cations, such as Ca2+ and Zn2+, in addition to aiding in the absorption of essential dietary minerals. α-Lactalbumin is a calcium-binding protein that can also bind iron and zinc with lower affinity. Current evidence suggests that α-lactalbumin has a stimulating effect on the absorption of these minerals. However, it is possible that an enhancing effect of α-lactalbumin on iron status was too small to detect during short study periods, and an improvement in iron status would be noted during a longer period of consumption.
Evidence strength: Mechanistically credible, supported by in vitro and animal studies and consistent with the protein's known calcium-binding chemistry. Human clinical evidence for mineral absorption enhancement specifically attributable to α-LA supplementation is limited and indirect.
α-Lactalbumin is available as:
Specific dosages reported in clinical studies include:
A considerable proportion of the research remains confined to cell and animal experiments, and it remains uncertain whether findings will be replicated in humans, and at what dosage.
Bovine α-lactalbumin has been affirmed as Generally Recognized As Safe (GRAS) for use in cow's milk-based non-exempt infant formula by the U.S. FDA (GRAS Notices GRN 000809 and GRN 000909). Clinical trials have confirmed that formulas enriched with α-lactalbumin are safe, support adequate growth, increase energetic efficiency, and improve gastrointestinal tolerance in infants.
α-Lactalbumin is a recognized cow's milk allergen, registered as Bos d 4. The significant allergens in cow's milk belong to casein proteins and whey proteins (alpha-lactalbumin and beta-lactoglobulin). Most individuals with cow's milk allergies have a sensitivity to both caseins and whey proteins.
Children with cow's milk allergy are mostly sensitized to multiple cow's milk proteins. Sensitization can be found to caseins and/or to whey proteins, such as α-lactalbumin (Bos d4) and β-lactoglobulin (Bos d5).
A study focusing on adverse events during milk oral immunotherapy highlighted the inherent risks compared to allergen avoidance and identified higher IgE levels for α-lactalbumin and casein at baseline as risk factors for anaphylactic reactions during oral immunotherapy.
Casein is heat stable and is not destroyed through cooking. On the other hand, the proteins beta-lactoglobulin and alpha-lactalbumin are heat sensitive. Therefore patients who only react to these heat-sensitive proteins may be able to tolerate products containing milk that has been cooked or baked.
All marketed milk and milk products have undergone industrial processing that involves heating, filtration, and defatting. Milk processing results in structural changes of immunomodulatory proteins, leads to a loss of lipophilic compounds in the matrix, and hence to a higher allergenicity of industrially processed milk products. Thereby, the tolerogenic capacity of raw farm milk, associated with the whey proteins α-lactalbumin and β-lactoglobulin and their lipophilic ligands, is lost.
Many people with a cow's milk allergy are also allergic to sheep's or goat's milk. This is because the proteins in the milk of other animals are similar to those found in cow's milk and can also be considered dangerous by the immune system.
Because α-lactalbumin is a co-enzyme of lactose synthase — the enzyme that produces lactose — preparations derived from lactose-containing dairy fractions are generally contraindicated in individuals with galactosaemia, a metabolic disorder of galactose metabolism.
While the binding of Ca2+ increases stability of α-LA, the binding of Zn2+ to the Ca2+-loaded protein decreases its stability and causes its aggregation. This interaction is physiologically relevant in the context of zinc availability in milk and infant nutrition.
Because the primary putative mechanism of action for neurological effects involves elevation of circulating tryptophan, individuals taking other tryptophan-raising interventions (e.g., 5-HTP supplements, selective serotonin reuptake inhibitors, or monoamine oxidase inhibitors) should be aware of potential additive serotonergic effects, though direct interaction studies with α-LA specifically are not documented in the available clinical literature.
Health conditions that Lactalbumin may help support.
Body systems that Lactalbumin may help support.
Go back